Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;29(1):2959-2970.
doi: 10.1080/10717544.2022.2120566.

Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer

Nasrul Wathoni  1   2 , Lisa Efriani Puluhulawa  1 , I Made Joni  2   3 , Muchtaridi Muchtaridi  3   4 , Ahmed Fouad Abdelwahab Mohammed  5   6 , Khaled M Elamin  7 , Tiana Milanda  8 , Dolih Gozali  1
Affiliations
Review

Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer

Nasrul Wathoni et al. Drug Deliv. 2022 Dec.

Abstract

Lung cancer is the second most common type of cancer after breast cancer. It ranks first in terms of mortality rate among all types of cancer. Lung cancer therapies are still being developed, one of which makes use of nanoparticle technology. However, conjugation with specific ligands capable of delivering drugs more precisely to cancer sites is still required to enhance nanoparticle targeting performance. Monoclonal antibodies are one type of mediator that can actively target nanoparticles. Due to the large number of antigens on the surface of cancer cells, monoclonal antibodies are widely used to deliver nanoparticles and improve drug targeting to cancer cells. Unfortunately, these antibodies have some drawbacks, such as rapid elimination, which results in a short half-life and ineffective dose. As a result, many of them are formulated in nanoparticles to minimize their major drawbacks and enhance drug targeting. This review summarizes and discusses articles on developing and applying various types of monoclonal antibody ligand nanoparticles as lung cancer target drugs. This review will serve as a guide for the choice of nanoparticle systems containing monoclonal antibody ligands for drug delivery in lung cancer therapy.

Keywords: Active targeting; drug delivery; lung cancer; monoclonal antibodies; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Number of articles used by year.
Figure 2.
Figure 2.
Flowchart of methodology.
Figure 3.
Figure 3.
Targeted drug delivery system using monoclonal antibody.
Figure 4.
Figure 4.
Types of monoclonal antibody used as targeted nanoparticles for lung cancer.
Figure 5.
Figure 5.
Characteristic of each type of nanoparticles.
See this image and copyright information in PMC

References

    1. Abbas Z, Rehman S. (2018). An overview of cancer treatment modalities. Neoplasm 1:139–157.
    1. Abdi N, Shahbazi-Gahrouei D. (2021). Assessment of superparamagnetic iron oxide nanoparticles conjugated with anti-epidermal growth factor receptor antibody for the detection of lung cancer by Magnetic Resonance Imaging (MRI) in C57BL/6. J Isfahan Med Sch 38:1038–42.
    1. Abd-Rabou AA, Ahmed HH. (2019). Bevacizumab and CCR2 inhibitor nanoparticles induce cytotoxicity-mediated apoptosis in doxorubicin-treated hepatic and non-small lung cancer cells. Asian Pac J Cancer Prev 20:2225–38. - PMC - PubMed
    1. Adams GP, Weiner LM. (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–57. - PubMed
    1. Alavi M, Hamidi M. (2019). Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther 34:1–8. - PubMed